A Meta-Analysis of Topiramate's Effects for Individuals with Alcohol Use Disorders
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Influenced by several trials and reviews highlighting positive outcomes, topiramate is increasingly prescribed as a treatment for alcohol use disorders (AUDs). The only previously published meta-analysis of topiramate for AUDs was limited by a sample of only 3 randomized, placebo-controlled trials (RCTs). METHODS: A systematic search identified 7 RCTs (including a total of 1,125 participants) that compared topiramate to placebo for the treatment for AUDs. This meta-analysis estimated the overall effects of topiramate on abstinence, heavy drinking, craving, and γ-glutamyltranspeptidase (GGT) outcomes and included several sensitivity analyses to account for the small sample of studies. RESULTS: Overall, the small to moderate effects favored topiramate, although the effect on craving was not quite significantly different from 0. The largest effect was found on abstinence (g = 0.468, p < 0.01), followed by heavy drinking (g = 0.406, p < 0.01), GGT (g = 0.324, p = 0.02), and craving (g = 0.312, p = 0.07) outcomes. Sensitivity analyses did not change the magnitude or direction of the results, and tests did not indicate significant publication bias. The small sample size did not allow for examination of specific moderators of the effects of topiramate. CONCLUSIONS: Topiramate can be a useful tool in the treatment of AUDs. Its efficacy, based on the current sample of studies, seems to be of somewhat greater magnitude than that of the most commonly prescribed medications for AUDs (naltrexone and acamprosate). Further research will help to identify the contexts in which topiramate is most beneficial (e.g., dose, concurrent psychotherapy, patient characteristics).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Handbook of Research Synthesis and Meta-Analysis
(2019) · doi:10.7758/9781610448864 · Cited by 4,553
Robust variance estimation in meta‐regression with dependent effect size estimates
Hedges, L. V., Tipton, E., & Johnson, M. C. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.5 · Cited by 2,086
Improved tests for a random effects meta‐regression with a single covariate
Knapp, G., & Hartung, J. (2003) · Statistics in Medicine · doi:10.1002/sim.1482 · Cited by 2,075
Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model
Viechtbauer, W. (2005) · Journal of Educational and Behavioral Statistics · doi:10.3102/10769986030003261 · Cited by 1,699 · cited 1×
“We calculated overall effect sizes under a restricted maximum likelihood random-effects model (Viechtbauer, 2005), given our goal of generalizability and our assumption of heterogeneity of effects (Raudenbush, 2009).”
Psychometric properties of the Penn Alcohol Craving Scale
Flannery, B. A., Volpicelli, J. R., & Pettinati, H. M. (1999) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04349.x · Cited by 852
Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Cuijpers, P., van Straten, A., Bohlmeijer, E., Hollon, S. D., & Andersson, G. (2010) · Psychological Medicine · doi:10.1017/s0033291709006114 · Cited by 533
Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time
Trikalinos, T. A., Churchill, R., Ferri, M., Leucht, S., Tuunainen, A., Wahlbeck, K., & Ioannidis, J. P. A. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.02.018 · Cited by 177
Comparing topiramate with naltrexone in the treatment of alcohol dependence
Baltieri, D. A., Daró, F. R., Ribeiro, P. L., & De Andrade, A. G. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02355.x · Cited by 145
Kampman, K. M., Pettinati, H. M., Lynch, K. G., Spratt, K., Wierzbicki, M. R., & O’Brien, C. P. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.05.026 · Cited by 115
Regression to the mean in substance use disorder treatment research
Finney, J. W. (2008) · Addiction · doi:10.1111/j.1360-0443.2007.02032.x · Cited by 78
Self-citationLikhitsathian, S., Uttawichai, K., Booncharoen, H., Wittayanookulluk, A., Angkurawaranon, C., & Srisurapanont, M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.06.032 · Cited by 46 · cited 10×
“Four of the 6 studies required that individuals complete some period of abstinence before participating in the trial (Baltieri et al., 2008; Kampman et al., 2013; Likhitsathian et al., 2013; Rubio et al., 2009).”
Influential
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Kranzler, H. R., & Soyka, M. (2018) · JAMA · doi:10.1001/jama.2018.11406 · Cited by 580
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“A meta-analysis including seven RCTs of topiramate for AUD with a total of 1125 participants found that topiramate significantly increased number of days abstinence and decreased heavy-drinking days compared to placebo [118].”
MethodResultA meta-analysis of the efficacy of gabapentin for treating alcohol use disorder
Kranzler, H. R., Feinn, R., Morris, P., & Hartwell, E. E. (2019) · Addiction · doi:10.1111/add.14655 · Cited by 121
Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?
Mann, K., Aubin, H.-J., & Witkiewitz, K. (2017) · European Addiction Research · doi:10.1159/000481348 · Cited by 93
Metadata
- Authors
- Blodgett, J. C., Del Re, A. C., Maisel, N. C., & Finney, J. W.
- Venue
- Alcoholism: Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 2014-05-05
- Volume
- 38
- Issue
- 6
- Pages
- 1481-1488
- ISSN
- 0145-6008 (ISSN-L)
- OpenAlex
- W2104086074
- Cited by
- 188
- References
- 12
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.